

PRESS RELEASE

4 December 2018

## OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

**Swedish life science company, OnDosis, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development of an ADHD treatment for the US market.**

The new treatment for the management of ADHD will be developed by Recipharm's Centre of Excellence in Oral Solids and will leverage OnDosis' proprietary technology which integrates oral drugs in form of micro units and individualised dosing, in a handheld device. The advantages are simplified titration, more accurate dosing and the ability to track dosing and treatment results.

Bernard Pluta, President, Development Services, commented: "The global ADHD market amounts to just over 10bn USD and there is strong demand for new solutions to help better manage this condition that affects a broad patient population. We are very proud to be able to work with OnDosis on such an important project and we believe that our excellent capabilities in drug formulation using coated pellets in Pessac, France, will be very valuable assets throughout the partnership."

"ADHD is a disease area with a significant unmet medical need. It has been confirmed in dialogue with patients and healthcare professionals that ADHD is an area which can gain significant benefits from the new treatment regimen made possible by OnDosis technology. The decision to commence development of a formulation, which will be integrated with OnDosis technology, marks an important milestone for our company and we're delighted to be working with Recipharm on this critical development work" said Martin Olovsson, CEO of OnDosis.

### Contact information

- Bernard Pluta, President Development Services Recipharm, [bernard.pluta@recipharm.com](mailto:bernard.pluta@recipharm.com), +33 634 617 537
- Martin Olovsson, CEO OnDosis, [m.olvsson@ondosis.com](mailto:m.olvsson@ondosis.com), +46 767 728 501

For media enquiries, please contact Lindsay Baldry at [ramarketing](mailto:ramarketing@ramarketingpr.com): [lindsay@ramarketingpr.com](mailto:lindsay@ramarketingpr.com), + 44 (0)191 222 1242, [www.ramarketingpr.com](http://www.ramarketingpr.com), Twitter: @ramarketingpr, Facebook: /ramarketingpr, LinkedIn: /remarketing

### About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm's turnover is approximately SEK 6.0 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit [www.recipharm.com](http://www.recipharm.com)

### About OnDosis

Swedish life science company OnDosis has developed a proprietary technology to deliver flexible and individualised dosing of oral medicines. By integrating medicines with intelligent dosing and digital capabilities in a handheld device, OnDosis offers a new way to take oral medicines – in micro units. Individualised, intuitive and connected. Initial focus areas are pain, ADHD and immunosuppression. OnDosis is a spin-out from AstraZeneca and headquartered in Gothenburg, Sweden.

More information at [www.ondosis.com](http://www.ondosis.com)

Follow us on LinkedIn: OnDosis